Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | DAO | P14920 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11315735 | 0.98 | HPGD (0.65) | HPGDMEN1KMT2ADAOKDM4E | |
| Hydrogen Sulfide SCHEMBL27583640 | 0.98 | HPGD (0.65) | HPGDMEN1KMT2ADAOKDM4E | |
| SCHEMBL22085424 | 0.85 | HPGD (0.49) | HPGDMEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL21724684 | 0.84 | KDM4E (0.48) | HPGDMEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL14826582 | 0.84 | HPGD (0.59) | HPGD | |
| SCHEMBL19236689 | 0.84 | KDM4E (0.48) | HPGDKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL6719842 | 0.81 | ALDH1A1 (0.52) | HPGDKMT2ADAOKDM4ECYP1A2 | |
| SCHEMBL22034371 | 0.80 | KDM4E (0.45) | HPGDKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL24495513 | 0.80 | DAO (0.72) | HPGDMEN1KMT2ADAOMAPK1 | |
| SCHEMBL3996660 | 0.80 | HPGD (1.00) | HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3977130-B1 | METHODS FOR MODULATING A TREATMENT REGIMEN | INST NAT SANTE RECH MED (FR) | 2024-07-24 | — | — | EP | disclosed |
| US-20220236276-A1 | METHODS FOR MODULATING A TREATMENT REGIMEN | UNIVERSITÉ PARIS CITÉ (FR) | 2022-07-28 | — | — | US | disclosed |
| US-20220160718-A1 | COMPOSITIONS AND METHODS OF TREATING CANCER | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| EP-3977130-A1 | METHODS FOR MODULATING A TREATMENT REGIMEN | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-04-06 | — | — | EP | disclosed |
| US-20220041627-A1 | PRODRUGS OF ANTI-CANCER AND ANTI-AUTOIMMUNE DISEASES THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-02-10 | — | — | US | disclosed |
| EP-3890742-A1 | PRODRUGS OF ANTI-CANCER AND ANTI-AUTOIMMUNE DISEASES THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USE THEREOF | University of Maryland, Baltimore (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020117938-A1 | PRODRUGS OF ANTI-CANCER AND ANTI-AUTOIMMUNE DISEASES THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20160152573-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160152573-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20080096907-A1 | Aryl, Pyrimidyl Compounds, Pharmaceutical Compositions Comprising them, Their Use as Antimicrobial Agents | INSTITUT PASTEUR (FR) | 2008-04-24 | — | — | US | disclosed |
| US-20080096907-A1 | Aryl, Pyrimidyl Compounds, Pharmaceutical Compositions Comprising them, Their Use as Antimicrobial Agents | INSTITUT PASTEUR (FR) | 2008-04-24 | — | — | US | disclosed |
| US-20080096907-A1 | Aryl, Pyrimidyl Compounds, Pharmaceutical Compositions Comprising them, Their Use as Antimicrobial Agents | INSTITUT PASTEUR (FR) | 2008-04-24 | — | — | US | disclosed |
| EP-1655288-A1 | Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents | INSTITUT PASTEUR (FR) | 2006-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096907-A1 | Aryl, Pyrimidyl Compounds, Pharmaceutical Compositions Comprising them, Their Use as Antimicrobial Agents | TPMT, DHFR, TYMP | HPGD 327/4885MEN1 4142/4885KMT2A 4090/4885 |
| US-20220160718-A1 | COMPOSITIONS AND METHODS OF TREATING CANCER | CCR2, CCR5, CXCR3 | HPGD 1069/4885MEN1 4320/4885KMT2A 1167/4885 |
| US-20160152573-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | DDT, DPYD, DNPEP | HPGD 298/4885MEN1 436/4885KMT2A 2020/4885 |
| US-20220041627-A1 | PRODRUGS OF ANTI-CANCER AND ANTI-AUTOIMMUNE DISEASES THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USE THEREOF | ENPP2, PAICS, TPMT | HPGD 238/4885MEN1 297/4885KMT2A 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.